ANIK Q2 2019 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q2 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$30M-0.4% YoY

Gross Profit

$24M77.5% margin

Operating Income

$12M39.2% margin

Net Income

$9M31.0% margin

EPS (Diluted)

$0.67

QoQ Revenue Growth

+23.0%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$287M

Total Liabilities

$36M

Stockholders' Equity

$251M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$31M	-0.4%
Gross Profit	$24M	$22M	+5.3%
Operating Income	$12M	$11M	+5.9%
Net Income	$9M	$10M	-6.5%

Revenue Segments

Product

$30M50%

Orthobiologics

$26M44%

Surgical

$2M3%

Manufactured Product, Other

$1M2%

Dermal

$444,0001%

Geographic Segments

UNITED STATES

$23M82%

Europe

$5M18%